[Featured Stock] Hyundai Bio Rises 11% on News of COVID-19 Treatment Phase 3 Clinical Trial Plan Submission...

Hyundai Bio is rising more than 11%.

As of 10:02 AM on the 28th, Hyundai Bio is trading at 20,900 KRW, up 11.76% (2,200 KRW) from the previous trading day. This is interpreted as a reaction to the news that Hyundai Bio has applied for approval from the Ministry of Food and Drug Safety for the phase 3 clinical trial plan of its COVID-19 treatment drug, Zepty (CP-COV03).

Hyundai Bio announced after the market closed on the 27th that it had applied for approval from the Ministry of Food and Drug Safety for the phase 3 clinical trial plan of its COVID-19 treatment drug Zepty (CP-COV03). Previously, in April of last year, Hyundai Bio disclosed that in the phase 2 clinical trial conducted on 300 adults aged 19 and older, including 120 high-risk patients, no serious adverse reactions occurred, and the drug showed effectiveness by improving 12 COVID-19 symptoms after administration.

Hyundai Bio plans to continue pursuing emergency use authorization for Zepty based on the existing clinical trial results, independently from the ongoing phase 3 clinical trial.

This content was produced with the assistance of AI translation services.